WHC is still in active development. Read this to understand our approach.
depiction of XPOQHMRABVBWPR-UHFFFAOYSA-N.svg
psychonaut

Efavirenz

Check on psychonaut

isomerdesign

Efavirenz

Check on isomerdesign

pubchem

Efavirenz

Check on pubchem

drugmap

Efavirenz

Check on drugmap

wiki

Efavirenz

Check on wiki

Data

InChI: InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)

Synonyms: SR-01000759360-4,Efavirenz & IL-28B,6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one,CHEBI:119486, (-)-Efavirenz,NCGC00159337-02,EFAVIRENZ [MART.], (4S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one,EFAVIRENZ [WHO-DD],MFCD05662344, Sustiva, (S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-ben, (4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one, L-743,726,Z2186909878,(S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-ben zoxazin-2-one,(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-2,4-dihydro-1H-3,1-benzoxazin-2-one,JE6H2O27P8,EFAVIRENZ [INN],DMP266,Z2177953192,Efavirenz & Interleukin 28B,HMS3713M14,EFAVIRENZ COMPONENT OF ATRIPLA,NCGC00159337-12,(S)-6-Chloro-4-(cyclopropyl-ethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazine-2-one,Efavirenz & Interferon lambda-1,Sustiva,ATRIPLA COMPONENT EFAVIRENZ,EFV & Interferon lambda-2,Efavirenz [USP:INN:BAN],EFV & IFNL1,Stocrin,DMP-266,HMS2051J08,AB00639956-08,Efavirenz & Interferon lambda-2,598E524, L-741211, Strocin (TM),EFAVIRENZ [JAN],SR-01000759360, Stocrin (TN),UNII-JE6H2O27P8,(S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one,DB00625,NSC-742403,HSDB 7163,Efavirenz- Bio-X,(Rac)-DMP 266; (Rac)-EFV; (Rac)-L-743726,(S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one, 6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one,Efavirenz & IFNL2,L-743,726,HY-10572, (S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one,F17329,J-520431,Efavirenzum,Efavirenz & Interferon lambda-3,(4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one,E0997,AC-25006,Efavirenz & IL-29,NSC 742403,DMP 266,DTXSID9046029,EFV & Interleukin 29,2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)-,Efavirenz teva,DSSTox_GSID_46029, Sustiva (TN), Stocrin,(S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one,C08088,MLS001424087,EFAVIRENZUM [WHO-IP LATIN],Efavirenz, (S),EFAVIRENZ [USP MONOGRAPH],(S)-Efavirenz,GTPL11287,Strocin (TM),BCPP000245,Efavirenz (JAN/USP/INN),AB21723,efavirenz,L 743726,CHEMBL223228, (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one,SCHEMBL37762,CAS-154598-52-4,KS-5380,Efavirenz & Poly-lactide-co-glycolide, DMP 266,(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one,NCGC00159337-04,EFAVIRENZ [USAN],AB00639956-06,EFV & IL-28A,EFV & IL-28B,Viraday,Efavirenz solution, 1.0 mg/mL in acetonitrile, certified reference material,A809555,2H-3, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)-,(-)-6-CHLORO-4-CYCLOPROPYLETHYNYL-4-TRIFLUOROMETHYL-1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONE, Efavirenz (JAN/INN),(S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-(S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one,Efavirenz,EFV & IFNL3,Efavirenz & IFNL1,HMS3393J08,EN300-219935,Efavirenz & PLGA,EFAVIRENZ [EMA EPAR], Eravirenz,(4S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one,HMS2090N16,EFV, Sustiva (TM),Efavirenz & IFNL3,Sustiva (TN), 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)-(9,Efavirenz & Interleukin 28A,EFAVIRENZ [VANDF],EFAVIRENZ [WHO-IP],SMR000466351,Met-SDF-1.beta. & Efavirenz,D00896,154598-52-4,s4685,EFAVIRENZ [MI],(S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, EFZ,CCG-101011,SR-01000759360-5,ZINC2020233, DMP-266,Efavirenz 100 microg/mL in Acetonitrile,BCP27719,(-)-Efavirenz,EFAVIRENZ [HSDB],Q422645,BIDD:GT0383,Sustiva (TM),EFV & Interleukin 28B, L 743726,Tox21_111582_1,AMY229,(4S)-6-chloranyl-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one,EFV & IL-29,AKOS015894951,(S)-6-CHLORO-4-(CYCLOPROPYLETHYNYL)-4-(TRIFLUOROMETHYL)-1H-BENZO[D][1,3]OXAZIN-2(4H)-ONE,1ikw,TELURA COMPONENT EFAVIRENZ,Efavirenz & Interleukin 29,NSC742403,EFV & IFNL2,NC00261,DSSTox_RID_81298,EFAVIRENZ [ORANGE BOOK],2H-3,1-Benzoxazin-2-one, 6-chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)-, Efavirenz, (S)-isomer,L-743726,EFAVIRENZ [USP-RS],DL-535,Efavirenz Ready Made Solution,BC164402,DSSTox_CID_26029, Zoxazin-2-one,Efavirenz, United States Pharmacopeia (USP) Reference Standard,MLS000759465,BCP9000636,Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz,Tox21_111582, Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz, L-743726,1ikv,EFV & Interleukin 28A,(s)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one,BDBM2483,(4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one,Efavirenz, >=98% (HPLC),EFV & Interferon lambda-3,Eravirenz,EFV & Interferon lambda-1, L-743725, (4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one,NCGC00271713-05,Efavirenz & IL-28A,(Rac)-Efavirenz, Met-SDF-1.beta. & Efavirenz,NCGC00271713-08,EFV & PLGA, (S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one,DMP-266; Efavirenz


Estimated data

Solubility: -5.093 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: No (prediction using frontiersin.org)

Addictivity Prediction: 32.4% (prediction based on www.mdpi.com)

Similarities

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.